HAVCR2 and acute myeloid leukemia: t(8;21) and inv(16) patients exhibited no significant difference in the frequency of CD34+TIM-3+ cells (p = 0.97), but both exhibited markedly higher TIM-3+ frequencies than non-CBF-AML patients (19.3% (1.7–64.2%) vs. 4.0% (0.18–58.7%), p < 0.001; 17.5% (8.9–33.1%) vs. 4.0% (0.18–58.7%), p = 0.002).